Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.32 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.32 |
| ▸ | GAK | O14976 | 1/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463471 | 0.84 | CTSK (0.41) | CTSKCTSCIP6K1TRPA1AVPR2 | |
| SCHEMBL2461130 | 0.80 | IP6K1 (0.40) | CNR1IP6K1CNR2NPC1 | |
| SCHEMBL2458971 | 0.78 | IP6K1 (0.38) | CNR1IP6K1CNR2NPC1 | |
| SCHEMBL2461911 | 0.76 | IP6K1 (0.36) | CNR1IP6K1CNR2NPC1 | |
| SCHEMBL2461992 | 0.75 | ADRB1 (0.37) | CNR1IP6K1CNR2 | |
| SCHEMBL3452434 | 0.75 | IP6K1 (0.42) | CTSKCNR1IP6K1CNR2SYK | |
| SCHEMBL2463575 | 0.74 | NR1H3 (0.42) | IP6K1 | |
| SCHEMBL9041963 | 0.73 | IP6K1 (0.40) | CTSKCTSCIP6K1ALDH1A1MAPT | |
| SCHEMBL2463564 | 0.72 | CNR1 (0.37) | CNR1CNR2NPC1 | |
| SCHEMBL2463505 | 0.71 | HDAC1 (0.39) | CNR1IP6K1CNR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | CTSK 1380/4885CTSC 1399/4885CNR1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.